These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 7693261)

  • 1. [Recombinant plasma proteins for therapeutic use--status and developmental trends].
    Storch H
    Beitr Infusionsther; 1993; 31():31-7. PubMed ID: 7693261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biotechnology: alternatives to human plasma-derived therapeutic proteins.
    Lynch TJ
    Baillieres Best Pract Res Clin Haematol; 2000 Dec; 13(4):669-88. PubMed ID: 11102283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Current status and trends in blood biologicals].
    Wang Z; Zhao X; Lv M; Zhang J
    Sheng Wu Gong Cheng Xue Bao; 2011 May; 27(5):730-46. PubMed ID: 21845840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical importance of human plasma proteins and their future development].
    Schwick HG
    Beitr Infusionsther; 1991; 28():115-23. PubMed ID: 1725608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The factor VIII/von Willebrand factor complex: basic and clinical issues.
    Federici AB
    Haematologica; 2003 Jun; 88(6):EREP02. PubMed ID: 12826528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.
    Gaboulaud V; Parquet A; Tahiri C; Claeyssens S; Potard V; Faradji A; Peynet J; Costagliola D;
    Br J Haematol; 2002 Feb; 116(2):383-9. PubMed ID: 11841442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chemistry and clinical significance of human plasma proteins].
    Haupt H
    Behring Inst Mitt; 1990 Oct; (86):1-66. PubMed ID: 2252458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges for new haemophilia products from a manufacturer's perspective.
    Schulte S
    Thromb Res; 2014 Nov; 134 Suppl 1():S72-6. PubMed ID: 24360931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
    Hedner U
    Thromb Haemost; 1999 Aug; 82(2):531-9. PubMed ID: 10605747
    [No Abstract]   [Full Text] [Related]  

  • 10. Recombinant clotting factors.
    Pipe SW
    Thromb Haemost; 2008 May; 99(5):840-50. PubMed ID: 18449413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.
    Auerswald G; Spranger T; Brackmann HH
    Haematologica; 2003 Jun; 88(6):EREP05. PubMed ID: 12826531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant factor IX.
    White GC; Beebe A; Nielsen B
    Thromb Haemost; 1997 Jul; 78(1):261-5. PubMed ID: 9198163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquired haemophilia in association with type III von Willebrand's disease: successful treatment with high purity von Willebrand's factor and recombinant factor VIIa.
    Majumdar G; Phillips JK; Lavallee H; Savidge GF
    Blood Coagul Fibrinolysis; 1993 Dec; 4(6):1035-7. PubMed ID: 8148477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in clotting factor treatment for congenital hemorrhagic disorders.
    Tarantino MD; Aledort LM
    Clin Adv Hematol Oncol; 2004 Jun; 2(6):363-8. PubMed ID: 16163206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Traceability of drugs derived from blood: regulation and pharmaco-economic implications after 24 months of application in Paris CHU].
    Lesne-Hulin A; Bourget P; Silvie M; Barath V; Singlas E
    Pathol Biol (Paris); 1997 Nov; 45(9):741-50. PubMed ID: 9538473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant coagulation factors.
    Roddie PH; Ludlam CA
    Blood Rev; 1997 Dec; 11(4):169-77. PubMed ID: 9481447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New approaches to haemophilia treatment--recombinant and transgenic concentrates, gene therapy and engineered coagulation factors].
    Habart D
    Cas Lek Cesk; 2006; 145(2):104-11. PubMed ID: 16521398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The evidence for the use of recombinant factor VIIa in massive bleeding: development of a transfusion policy framework.
    Moltzan CJ; Anderson DA; Callum J; Fremes S; Hume H; Mazer CD; Poon MC; Rivard G; Rizoli S; Robinson S
    Transfus Med; 2008 Apr; 18(2):112-20. PubMed ID: 18399845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New high-technology products for the treatment of haemophilia.
    Pipe SW; Saint-Remy JM; Walsh CE
    Haemophilia; 2004 Oct; 10 Suppl 4():55-63. PubMed ID: 15479373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of the bleeding inhibitor patient.
    Astermark J
    Semin Thromb Hemost; 2003 Feb; 29(1):77-86. PubMed ID: 12640569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.